Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) studying neurobehavior seek patients with neuroacanthocytosis (X-linked [McLeod syndrome], non-X-linked, and sporadic patients are eligible) to examine the role of the basal ganglia in this disease.
Eligible patients must be referred by a physician, should be ambulatory, and must be able to travel to Bethesda, MD, for testing. They should present with acanthocytosis either in the setting of the McLeod phenotype or in association with neurological signs such as neuromyopathy or cerebral involvement. Patients with abetalipoproteinemia (Bassen-Kornzweig) or neuroaxonal dystrophy (Hallervorden-Spatz) are not eligible.
The studies will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, and will include experimental neuropsychological testing, functional and structural neuroimaging, and a neurological evaluation. All study-related expenses will be paid by the NIH.
For more information, physicians should contact Dr. Adrian Danek, Cognitive Neuroscience Section, NINDS, NIH, Building 10, Room 5C205, 10 Center Drive MSC 1440, Bethesda, MD 20892-1440; telephone: 301-402-6395; e-mail: email@example.com.